Jump to any asset
850 assets, updated daily
As of September 11, 2026, Bristol-Myers Squibb Company (BMY) trades at $63.37. CleaRank Financial AI rates it Hold with a fair value of $68.00, 7.3% above the current price. Wall Street's consensus target is $68.00 across 28 analysts. RSI at 29 is in oversold territory, and the price is below its 50-day average of $63.42.
Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company NYSE
$63.37
-0.3800 (-0.60%)
Latest Price
AI Analyst Consensus
59 / 100
Bristol-Myers Squibb Company (BMY) is trading at $63.37, below its 50-day SMA but above its 200-day SMA. The stock's RSI is in oversold territory, indicating potential for a short-term bounce. However, recent insider transactions show a net seller position, with $140.8M in total sales versus $3.3M in total purchases, signaling a moderate sell signal from management. Wall Street analysts maintain a neutral consensus rating, with a median price target of $68.00, suggesting a modest 7.3% upside from current levels. The company's revenue growth is projected to be around 4.00% for the current quarter and 3.00% for the full year, with a projected decline of 3.00% for next year, indicating a slowing growth trajectory. Despite the oversold technicals, the prevailing insider selling and neutral analyst sentiment temper immediate bullish enthusiasm. Investors should monitor upcoming earnings reports and pipeline developments for potential catalysts. The company's dividend yield of approximately 3.96% offers some income support, but the overall outlook suggests a period of consolidation rather than significant appreciation in the near term. Key risks include increased competition within the pharmaceutical sector and potential pipeline setbacks.
BMY Price Analysis
Market Metrics
Open
$64.19
Day Range
$63.27 to $64.19
Prev Close
$63.75
Volume
321.8K
52-Week Range
$42.52 to $68.64
Market Cap
$130.22B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a notable discount to sector peers (-45%), which may indicate undervaluation or specific company headwinds.
BMY Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, BMY beat estimates 4 times. The stock rose 3 times the next day. Price tends to react positively to beats.
BMY Analysis
Company's Health
3/5
12-Month Analyst Target
+7.31% Upside
Median of 28 analysts (12-month)
$68.00
AI Technical Analysis
At 28.54, Bristol-Myers Squibb Company's RSI is in oversold territory, suggesting a potential for a near-term price reversal. The stock is trading below its 20-day EMA ($65.47) and 50-day SMA ($63.42), indicating bearish short-term momentum, but remains above its 200-day SMA ($58.49), suggesting a longer-term uptrend is still intact. MACD is slightly positive at 0.26, offering a neutral signal. Key support is identified around the $58.50 level (200-day SMA), while resistance lies at the 50-day SMA of $63.42 and the 20-day EMA of $65.47. Volume has been significantly below average recently, with the latest volume at 321,801 compared to an average of 6.7 million, which suggests a lack of conviction behind current price movements. The chart structure indicates that while oversold conditions may lead to a bounce, sustained upward momentum will require breaking through key moving averages and overcoming insider selling pressure.
ProTips
- Monitor Bristol-Myers Squibb Company's (BMY) pipeline developments closely, as success or failure in clinical trials represents a significant catalyst for future growth.
- Given the moderate insider selling, consider waiting for clearer signals of insider confidence or a confirmed technical breakout before initiating or increasing a position.
- The company's dividend yield of approximately 3.96% may appeal to income-focused investors, but ensure this is balanced against the company's growth prospects and potential volatility.
Key Catalysts
Bullish
Strong Q3 2026 Earnings Beat
Bristol-Myers Squibb Company (BMY) exceeded Q3 2026 EPS estimates by 27.5%, leading to a positive price reaction, indicating potential for improved operational performance.
Source: Earnings ReportBearish
Moderate Insider Selling Signal
Insiders have sold $4.6 million worth of BMY stock against $202.2 thousand in purchases, indicating a moderate sell signal and potential lack of management confidence.
Source: Insider TransactionsBearish
Projected Revenue Decline in 2027
Revenue growth is projected to turn negative in 2027 (-3.00%), posing a risk to future earnings and valuation.
Source: Wall Street EstimatesNeutral
Wall Street Analyst Ratings
The majority of Wall Street analysts maintain a 'Hold' rating, with a median price target of $68.00, suggesting limited near-term upside.
Source: Analyst ConsensusMarket Outlook
The base case scenario for Bristol-Myers Squibb Company (BMY) suggests a period of consolidation, with potential for a modest recovery towards its median analyst target price of $68.00 over the next 6-12 months, representing a 7.3% upside. The stock's current oversold technical condition could support a short-term bounce, but sustained growth will depend on overcoming slowing revenue projections and competitive pressures. Upside catalysts could include stronger-than-expected pipeline developments or a significant positive earnings surprise that reverses the current insider selling sentiment. Conversely, downside risks include continued revenue contraction, increased competition impacting market share, or adverse clinical trial results. The company's ability to successfully launch new products and manage its patent expirations will be critical for long-term performance.
Key Statistics
| Market Cap | 130.22B |
|---|---|
| P/E Ratio | 14.04 |
| EPS (TTM) | 4.54 |
| Dividend Yield | 3.96% |
| 52 Week High | 68.64 |
| 52 Week Low | 42.52 |
Bristol-Myers Squibb Company (BMY) trades at a P/E ratio of 14.04, which is below the sector average of 25.5, suggesting a potentially attractive valuation relative to its peers. With an EPS of $4.54, the stock appears reasonably priced based on current earnings. However, projected revenue growth is slowing, with the next year's estimate at -3.00%, which could temper future earnings potential. The company's balance sheet strength and profitability metrics, such as net profit margin and return on equity, would provide further context for this valuation, but are not explicitly detailed. The current valuation, while appearing inexpensive on a P/E basis, must be considered alongside the decelerating revenue growth outlook and the moderate insider selling. Investors should assess whether the current price adequately discounts the future growth challenges. The dividend yield of approximately 3.96% provides a component of return, but the primary driver for stock appreciation will depend on the company's ability to innovate and grow its revenue streams in a competitive pharmaceutical market.
Earnings & Growth Analysis
Bristol-Myers Squibb Company recently reported an EPS of $2.04 for the quarter ending July 30, 2026, significantly beating the analyst estimate of $1.60 by 27.5%, leading to a 0.69% price increase. This follows a pattern of mixed earnings performance, with a beat in the prior quarter (Q2 2026) and a substantial EPS beat in Q1 2026, though the Q1 actual EPS of -$0.97 was still a loss compared to an estimated loss of -$3.78. The most recent quarter's strong beat suggests improving operational efficiency or successful product performance, but the overall trend indicates variability in earnings delivery.
Key Risks
A primary risk for Bristol-Myers Squibb Company is the moderate insider selling signal, with $4.6 million in sales versus $202.2 thousand in purchases, indicating a lack of strong conviction from management. Additionally, projected revenue growth is expected to turn negative next year (-3.00%), posing a challenge to future earnings expansion and potentially impacting the stock's valuation. Competition within the pharmaceutical sector remains intense, and any setbacks in the company's drug pipeline could significantly impact its long-term growth prospects.
Technical Indicators
| RSI (14) | 28.54 |
|---|---|
| MACD | 0.26 |
| SMA 50 | 63.42 |
| SMA 200 | 58.49 |
RSI
Oversold
SMA Cross
Bullish
Price vs SMA
Bearish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($63.42) above the 200-day SMA ($58.49), price is trading below the 50-day SMA, RSI at 28.5 suggests oversold conditions; potential bounce setup.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.15
Weak correlation
Nasdaq 100 (QQQ)
+0.02
Weak correlation
Bitcoin (BTC)
+0.02
Weak correlation
Gold (XAU)
+0.06
Weak correlation
Check Custom Correlation
Calculating correlation...
BMY Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies (click to switch)
CONSERVATIVE
$62.74
Slight discount to current
Wait for small dip
AGGRESSIVE
$63.37
At current price
Enter now if confident
Risk Management
STOP LOSS
$60.67
MAX LOSS
-3.3%
Volatility-Adjusted Stop Loss
Calculated based on RSI (28.5) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$64.62
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$65.87
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$67.76
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for BMY is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 11, 2026.Growth of $10,000
A $10,000 investment in BMY in September 2016 would be worth about $11,319 today, compared with about $35,030 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in BMY today could grow to about $14,660 by 2036 in the base case, with a bull case near $40,655 and a bear case around $5,287. Projections are statistical simulations, not guarantees.
BMY Stock Price Prediction: 2030
CleaRank's simulation projects a price near $73.85 for BMY by 2030 in the base case, from $63.37 today (1.2x over 4 years). The downside path ends near $38.74. These are outcomes of a Monte Carlo simulation run on BMY's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $47.69 | $65.84 | $90.90 |
| 2028 | $43.35 | $68.41 | $108 |
| 2029 | $40.65 | $71.08 | $124 |
| 2030 | $38.74 | $73.85 | $141 |
| 2031 | $37.30 | $76.73 | $158 |
| 2032 | $36.18 | $79.72 | $176 |
| 2033 | $35.28 | $82.83 | $194 |
| 2034 | $34.56 | $86.06 | $214 |
| 2035 | $33.98 | $89.42 | $235 |
| 2036 | $33.50 | $92.90 | $258 |
Method: 10,000 simulated price paths using BMY's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
BMY Insider Trading Analysis
Bought
$202.2K
1 Transactions
Sold
$4.6M
5 Transactions
Insiders
15
Active Traders
Avg Transaction
$792.8K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Feb 6, 2023 | CAFORIO GIOVANNI
Chief Executive Officer
|
Sell | 240.0K | $17.9M |
| Jul 30, 2021 | VESSEY RUPERT J
Officer
|
Sell | 158.4K | $10.8M |
| Dec 4, 2017 | LEUNG SANDRA
General Counsel
|
Sell | 156.6K | $9.9M |
| Sep 13, 2022 | ELKINS DAVID VINCENT
Chief Financial Officer
|
Sell | 134.0K | $9.6M |
| Aug 13, 2020 | LEUNG SANDRA
General Counsel
|
Sell | 141.4K | $8.9M |
| Aug 12, 2021 | ELKINS DAVID V
Chief Financial Officer
|
Sell | 99.7K | $6.7M |
| Mar 16, 2022 | VESSEY RUPERT J
Officer
|
Sell | 74.6K | $5.2M |
| Mar 2, 2020 | VESSEY RUPERT J
Officer
|
Sell | 84.3K | $5.1M |
| Jun 6, 2022 | LEUNG SANDRA
General Counsel
|
Sell | 65.0K | $4.9M |
| Nov 7, 2022 | VESSEY RUPERT J
Officer
|
Sell | 45.9K | $3.6M |
Page 1 of 1
Frequently Asked Questions
Is Bristol-Myers Squibb Company (BMY) stock a buy right now?
Bristol-Myers Squibb Company (BMY) currently holds a 'Hold' consensus rating from Wall Street analysts, with a median price target of $68.00, suggesting a modest 7.3% upside from its current price of $63.37. While the stock is trading in oversold territory technically, moderate insider selling and slowing revenue growth projections present headwinds.
What is Bristol-Myers Squibb Company's (BMY) stock price forecast for 2030?
Based on Monte Carlo simulations, Bristol-Myers Squibb Company's (BMY) stock price is projected to be $73.85 by 2030 under a base case scenario, with a downside projection of $38.74 and an upside projection of $140.77. These are statistical outcomes, not guaranteed price targets.
What are the biggest risks facing Bristol-Myers Squibb Company (BMY)?
The primary risks for Bristol-Myers Squibb Company (BMY) include moderate insider selling, a projected decline in revenue growth next year, and intense competition within the pharmaceutical industry. Pipeline setbacks could also negatively impact future growth.
How is Bristol-Myers Squibb Company (BMY) performing in terms of earnings?
Bristol-Myers Squibb Company (BMY) recently reported a significant EPS beat for the quarter ending July 30, 2026, exceeding estimates by 27.5%. However, earnings performance has been mixed in prior quarters, indicating some variability.
What is the dividend yield for Bristol-Myers Squibb Company (BMY)?
Bristol-Myers Squibb Company (BMY) offers a dividend yield of approximately 3.96%, providing some income return for investors.
How does Bristol-Myers Squibb Company (BMY) compare to its sector averages?
Bristol-Myers Squibb Company (BMY) trades at a P/E ratio of 14.04, which is below the healthcare sector average of 25.5, suggesting a potentially more attractive valuation. However, its projected revenue growth of -3.00% for next year is lower than the sector average of 10.0%.
What is the current technical outlook for Bristol-Myers Squibb Company (BMY) stock?
Bristol-Myers Squibb Company (BMY) is currently in oversold territory with an RSI at 28.5, but it is trading below its short-term moving averages (50-day SMA and 20-day EMA), indicating bearish short-term momentum. The stock remains above its 200-day SMA, suggesting the long-term uptrend is still in place.